Recent advances in genomic research led to the BC classification of defined molecular subtypes, based on hormone receptor (HR), including estrogen receptor (ER) and progesterone receptor (PR), expression, as well as ERBB2 [also known as human epidermal growth factor receptor 2 (HER2)]. This evidence concerns the gene ERBB2 and breast cancer.